A Phase 1, Open-label 6 Sequence 3 Period Crossover Study of Palbociclib (PD- 0332991) in Healthy Volunteers to Estimate the Relative Bioavailability of Palbociclib Formulations
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2014
Price : $35 *
At a glance
- Drugs Palbociclib (Primary)
- Indications Breast cancer; Colorectal cancer; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Multiple myeloma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 14 Mar 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 25 Feb 2014 New trial record
- 18 Feb 2014 Status changed from not yet recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.